Haleon plc 6-K, filed Jan 8, 2026
Haleon plc (HLN)
6-K
2026-01-08
For: 2026-01-08
View Original
Added on
April 05, 2026
About this 6-K
Haleon plc filed this 6-K on January 8, 2026.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2026
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
08
January 2026 - "Evolution of operating model"
|
99.1
Haleon announces evolution of its operating model to drive growth
and agility
08 January 2026: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE: HLN) has today announced
that it is evolving its operating model in support of its Win as
One strategy to drive its growth, productivity and culture agenda,
as set out at its Capital Markets Day in May 2025. These changes
are expected to be implemented by mid-2026.
Chief Growth Officer
Haleon has today created a new Chief Growth Officer (CGO) role.
This role will include broad responsibility across Haleon's
existing Category, Marketing and Strategy functions, as well as a
new global Commercial Excellence team. The CGO will lead Haleon's
growth and innovation agenda in partnership with Haleon's new
Operating Units (as below) and the existing R&D and Supply
Chain functions, to better leverage Haleon's global footprint and
capitalise on the strength and breadth of its brand portfolio, in
support of the ambitions set out in May 2025.
Operating Units
Haleon is creating six Operating Units (OUs) to enable the Company
to capitalise on the significant growth opportunities in its key
markets, with each OU responsible for delivering business
performance through the execution of Haleon's category
strategies.
The current EMEA & LatAm region will be separated into three
constituent OUs: Latin
America (LatAm), Middle
East and Africa (MEA)
and Europe. Recognising the strength of Haleon's business
in India
Subcontinent (ISC) and the
opportunities for growth, ISC will become its own OU, separate
from Asia Pacific. Haleon's North
America OU remains
unchanged.
Global Functions
Haleon's global functions remain responsible for setting functional
priorities in support of delivering its Win as One strategy and for
driving a consistent approach globally, making the right strategic
choices to benefit the end-to-end organisation. Haleon has
appointed a new Chief Transformation Officer (CTO), who will be
responsible for coordinating and driving the significant
transformation across Haleon's business processes, operating model,
and technology changes.
The CGO and CTO, along with the President of each OU, will be part
of Haleon's Executive Committee and will report directly to Chief
Executive Officer, Brian McNamara. Biographies for Haleon's full
Executive Team, including all newly appointed members, can be found
at www.haleon.com/who-we-are/leadership.
Brian McNamara, Chief Executive Officer of Haleon
commented: "In May 2025,
we introduced our Win as One strategy, which is how we will unlock
Haleon's full potential, as we transform into a world-class
consumer company. The changes we're making to our operating model
are an important part of us delivering against our strategy to
drive growth and will result in a simpler and more agile and
efficient organisation."
Haleon will share more detail as part of its Preliminary Full Year
Results scheduled for 25 February 2026 and will consult with
employee representatives as appropriate.
Enquiries
|
Investors
|
Media
|
||
|
Jo
Russell
|
+44
7787 392441
|
Zoë Bird
|
+44
7736 746167
|
|
Rakesh
Patel
|
+44
7552 484646
|
Victoria
Durman
|
+44 7894 505730
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
||
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans six major categories - Oral Health,
Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory
Health, Digestive Health and Therapeutic Skin Health and Other. Its
long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne,
Theraflu and Voltaren - are built on trusted science, innovation
and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
January 08, 2026
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|